Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q1
Sell
-31,148
Closed -$4.22M 120
2023
Q4
$4.22M Buy
+31,148
New +$3.59M 0.08% 91
2022
Q2
Sell
-46,363
Closed -$15.8M 147
2022
Q1
$15.8M Hold
46,363
0.26% 78
2021
Q4
$17.2M Buy
+46,363
New +$17.6M 0.22% 92
2019
Q3
Sell
-144,126
Closed -$51.6M 131
2019
Q2
$51.6M Sell
144,126
-89,538
-38% -$28.3M 0.8% 38
2019
Q1
$70.6M Sell
233,664
-19,121
-8% -$5.58M 1.09% 28
2018
Q4
$73.8M Sell
252,785
-22,205
-8% -$6.88M 1.36% 21
2018
Q3
$98.2M Sell
274,990
-17,476
-6% -$5.6M 1.18% 25
2018
Q2
$79.5M Hold
292,466
0.95% 35
2018
Q1
$67.3M Sell
292,466
-45,232
-13% -$10.4M 0.83% 41
2017
Q4
$71.8M Sell
337,698
-71,960
-18% -$14.8M 0.91% 37
2017
Q3
$79.4M Hold
409,658
0.76% 38
2017
Q2
$69.1M Buy
409,658
+78,745
+24% +$13.6M 0.72% 45
2017
Q1
$54.9M Buy
330,913
+143,611
+77% +$22.6M 0.62% 49
2016
Q4
$23.3M Sell
187,302
-322,072
-63% -$43.4M 0.3% 65
2016
Q3
$90M Sell
509,374
-360,520
-41% -$57.7M 1.03% 35
2016
Q2
$119M Sell
869,894
-55,306
-6% -$7.86M 1.24% 27
2016
Q1
$146M Buy
925,200
+23,644
+3% +$3.61M 1.54% 20
2015
Q4
$168M Sell
901,556
-281,672
-24% -$45.5M 1.52% 21
2015
Q3
$202M Hold
1,183,228
2.04% 16
2015
Q2
$251M Sell
1,183,228
-53,456
-4% -$10.4M 2.1% 14
2015
Q1
$223M Sell
1,236,684
-281,261
-19% -$53M 1.91% 21
2014
Q4
$273M Buy
1,517,945
+137,341
+10% +$24.2M 2.6% 10
2014
Q3
$220M Sell
1,380,604
-44,204
-3% -$7.39M 2.3% 13
2014
Q2
$247M Buy
1,424,808
+26,214
+2% +$3.91M 2.91% 9
2014
Q1
$202M Sell
1,398,594
-242,916
-15% -$35.7M 2.49% 10
2013
Q4
$177M Buy
1,641,510
+3,084
+0.2% +$282K 2.6% 13
2013
Q3
$129M Sell
1,638,426
-59,624
-4% -$4.56M 2.3% 14
2013
Q2
$124M Buy
+1,698,050
New +$109M 2.62% 10

Other funds holding ILMN

OrbiMed's ILMN Position: Q1 2024 in Review

OrbiMed sold out of Illumina (ILMN) in Q1 2024, closing a stake of 31,148 shares — an estimated $4.22M sold.

OrbiMed first reported a position in ILMN in Q2 2013 and held it in 28 quarters. The position peaked at $273M in Q4 2014. 795 funds tracked by Wall St. Rank hold ILMN as of Q1 2024.

  • OrbiMed reported no remaining Illumina position as of Q1 2024 after selling out during the quarter.
  • OrbiMed sold 31,148 Illumina shares in Q1 2024, an estimated $4.22M.
  • OrbiMed first reported a position in Illumina in Q2 2013 and held it in 28 quarters.
  • OrbiMed's Illumina position peaked at $273M in Q4 2014.
  • 795 funds tracked by Wall St. Rank held Illumina as of Q1 2024.

Based on OrbiMed's 13F filing for Q1 2024, filed 15 May 2024.